Liminatus Pharma, Inc. (LIMN)
3.76
+0.07
(+1.90%)
USD |
NASDAQ |
Oct 09, 16:00
3.78
+0.02
(+0.53%)
After-Hours: 20:00
Liminatus Pharma EPS Diluted (Quarterly) : -72.70 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -72.70 |
| March 31, 2026 | -78.02 |
| December 31, 2025 | -754.58 |
| September 30, 2025 | -168.78 |
| June 30, 2025 | 12.15 |
| March 31, 2025 | -0.936 |
| December 31, 2024 | -0.6565 |
| September 30, 2024 | -1.718 |
| June 30, 2024 | -1.848 |
| March 31, 2024 | -0.0005 |
| December 31, 2023 | -166.50 |
| September 30, 2023 | -99.62 |
| Date | Value |
|---|---|
| June 30, 2023 | 70.08 |
| March 31, 2023 | -195.10 |
| December 31, 2022 | -3.20 |
| September 30, 2022 | 197.92 |
| June 30, 2022 | 269.02 |
| March 31, 2022 | 276.50 |
| December 31, 2021 | -19.40 |
| September 30, 2021 | 490.00 |
| June 30, 2021 | -11.68 |
| March 31, 2021 | -142.28 |
| December 31, 2020 | -0.10 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.407M |
| Total Expenses (Quarterly) | 1.407M |
| Enterprise Value | -1.490M |
| Earnings Yield | -28.57K% |
| Normalized Earnings Yield | -14147.98 |